Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025 with a presentation and fireside chat starting at 2:15 p.m. PT / 5:15 p.m. ET. The event will be available via a live webcast on the company investor website.

A replay will be posted approximately two hours after the call and archived on the company website for about 90 days. Esperion is a commercial-stage biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with global approvals in >40 countries and a pipeline focused on ACLY biology and treatments for primary sclerosing cholangitis and renal diseases.

News Market Reaction

+2.70%

1 alert

+2.70% News Effect

On the day this news was published, ESPR gained 2.70%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 44th Annual Conference date: January 14, 2025 Presentation time PT: 2:15 p.m. PT +4 more

7 metrics

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Conference date January 14, 2025 Esperion presentation and fireside chat

Presentation time PT 2:15 p.m. PT Start of presentation and fireside chat

Presentation time ET 5:15 p.m. ET Start of presentation and fireside chat

Webcast archive period approximately 90 days Replay availability on company website

Marketed therapies two oral once-daily therapies Non-statin LDL-C lowering products

Global approvals more than 40 countries Geographic reach of marketed products

Market Reality Check

Price: $3.34 Vol: Volume 3,593,930 is at 0....

normal vol

$3.34 Last Close

Volume Volume 3,593,930 is at 0.72x the 20-day average, suggesting typical interest ahead of the event normal

Technical Price $3.71 is trading above the 200-day MA $2.05, indicating a pre-existing uptrend

Peers on Argus

Peers show mixed moves with AQST -1.38%, AKBA -4.91%, ORGO -10.52% and SIGA +1.6...

Peers show mixed moves with AQST -1.38%, AKBA -4.91%, ORGO -10.52% and SIGA +1.62%, indicating today’s backdrop is stock-specific rather than a coordinated sector move.

Historical Context

5 past events · Latest: Dec 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 19	Guideline endorsement	Positive	+3.4%	ACC statement recommending bempedoic acid for PAD patients with diabetes.
Dec 09	Inducement grants	Neutral	+1.1%	Equity awards to new CCO and employees under inducement plan.
Nov 21	Japan launch	Positive	+4.4%	Otsuka launch of NEXLETOL in Japan with near-term payment and royalties.
Nov 19	Conference appearance	Neutral	-1.4%	Piper Sandler healthcare conference presentation and webcast details.
Nov 18	Regulatory approval	Positive	+0.3%	Health Canada approval of NILEMDO for LDL‑cholesterol reduction.

Pattern Detected

Recent news has been largely positive (guideline inclusion, international launches, approvals) with stock reactions mostly positive and aligned, while conference appearance headlines have shown at least one mild negative divergence.

Recent Company History

Over the past few months, Esperion has reported several commercial and clinical milestones. On Nov 21, 2025, partner Otsuka launched NEXLETOL in Japan with tiered 15%–30% royalties and a $90M near‑term payment. Health Canada approved NILEMDO on Nov 18, 2025, supporting global expansion. A 2025 ACC scientific statement later recommended bempedoic acid for PAD and diabetes. Alongside these, Esperion announced a Piper Sandler conference appearance and inducement grants. Today’s J.P. Morgan conference participation fits this pattern of ongoing investor and commercial outreach.

Market Pulse Summary

This announcement highlights Esperion’s participation in the J.P. Morgan Healthcare Conference, offe...

Analysis

This announcement highlights Esperion’s participation in the J.P. Morgan Healthcare Conference, offering management a platform to update investors on its cardiometabolic and rare disease strategy. With global approvals across more than 40 countries and two oral non-statin LDL‑C therapies on the market, the company continues to emphasize commercial execution and pipeline development. Investors may watch for any new commentary on partnerships, pipeline programs such as Primary Sclerosing Cholangitis, and commercial performance trends.

Key Terms

cardiometabolic, orphan disease, acly biology, low-density lipoprotein cholesterol (LDL-C), +1 more

5 terms

cardiometabolic medical

"commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

orphan disease medical

"developing and delivering innovative cardiometabolic and rare/orphan disease therapies"

A rare medical condition that affects a very small number of people, often so few that standard drug development and commercial sales are impractical. For investors it matters because treatments for these conditions can qualify for special regulatory incentives, faster approval paths and price premiums, so a successful therapy is like owning a product that dominates a tiny but underserved niche market — high potential reward but also higher scientific and commercial risk.

acly biology medical

"The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines"

ACLY biology concerns the role of the enzyme ATP citrate lyase (ACLY) in converting cell fuel into acetyl units used to build fats and modify proteins, essentially acting like a factory machine that turns raw energy into construction materials for cells. Investors care because ACLY is a common drug target for conditions such as metabolic disease, fatty liver and some cancers; changes in ACLY-related research or therapies can affect the value of companies developing treatments or diagnostics.

low-density lipoprotein cholesterol (LDL-C) medical

"non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels"

Low-density lipoprotein cholesterol (LDL-C) is the portion of blood cholesterol carried by particles that deliver cholesterol to arteries; think of LDL-C as delivery trucks that can leave sticky deposits in vessel walls. Investors care because high LDL-C levels drive demand for tests, medications, medical devices and preventive care, influence clinical trial outcomes and regulatory decisions, and help determine future healthcare spending and revenue for companies in the cardiovascular sector.

primary sclerosing cholangitis medical

"including treatments for Primary Sclerosing Cholangitis and renal diseases"

A chronic disease in which the tubes that carry bile from the liver become inflamed and scarred, gradually blocking flow and potentially causing liver damage or failure; think of it like corrosion and narrowing in the body’s plumbing that disrupts normal cleanup and digestion. It matters to investors because there is no widely effective cure, so diagnostic advances, drugs, or procedures that slow progression can create meaningful commercial markets and clinical trial, regulatory and pricing risks that affect valuations in healthcare and biotech companies.

AI-generated analysis. Not financial advice.

ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025.

The company’s presentation and participation in a fireside chat will begin at 2:15 p.m. PT/5:15 p.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) present at the J.P. Morgan 44th Annual Healthcare Conference?

Esperion will present on Wednesday, January 14, 2025 at 2:15 p.m. PT / 5:15 p.m. ET.

How can investors watch the Esperion (ESPR) presentation at J.P. Morgan?

Investors can view the live webcast on Esperion’s investor website and access the replay there.

When will the Esperion (ESPR) webcast replay be available and for how long?

The replay will be available approximately two hours after the call and archived for about 90 days on the company website.

What topics will Esperion (ESPR) likely cover in its J.P. Morgan presentation?

The company will discuss its commercial-stage products, ACLY biology research, and its pipeline including programs for primary sclerosing cholangitis and renal diseases.

Who can I contact for investor inquiries about Esperion (ESPR)?

Investor inquiries can be directed to Alina Venezia at investorrelations@esperion.com or (734) 887-3903.

Does Esperion (ESPR) currently market any therapies and where are they approved?

Esperion currently markets two oral, once-daily, non-statin LDL-C therapies and reports global approvals in more than 40 countries.